Zentalis announces interim DENALI Part 1b data showing 15.8-month median overall survival with azenosertib in platinum-resistant ovarian cancer

Zentalis announced interim DENALI Part 1b data showing median overall survival of 15.8 months with azenosertib monotherapy in cyclin E1-positive platinum-resistant ovarian cancer.

Detected & updated continuously · Source: Nebula